Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

• By Derrick Gingery

Related Content

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

Sep 20 2016

FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Oct 27 2014

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Jan 14 2016

Related Companies

Sarepta Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Approvals Drug Approval Standards Drug Review Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window